Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis

Robin Jean Bell, Pam Fradkin, Max Allan Schwarz, Susan Ruth Davis

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation
Original languageEnglish
Pages (from-to)15 - 21
Number of pages7
JournalMenopause
Volume20
Issue number1
DOIs
Publication statusPublished - 2013

Cite this